These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26074872)

  • 1. Unbalanced Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinases Ratios Predict Hemorrhagic Transformation of Lesion in Ischemic Stroke Patients Treated with Thrombolysis: Results from the MAGIC Study.
    Piccardi B; Palumbo V; Nesi M; Nencini P; Gori AM; Giusti B; Pracucci G; Tonelli P; Innocenti E; Sereni A; Sticchi E; Toni D; Bovi P; Guidotti M; Tola MR; Consoli D; Micieli G; Tassi R; Orlandi G; Perini F; Marcello N; Nucera A; Massaro F; DeLodovici ML; Bono G; Sessa M; Abbate R; Inzitari D
    Front Neurol; 2015; 6():121. PubMed ID: 26074872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death.
    Inzitari D; Giusti B; Nencini P; Gori AM; Nesi M; Palumbo V; Piccardi B; Armillis A; Pracucci G; Bono G; Bovi P; Consoli D; Guidotti M; Nucera A; Massaro F; Micieli G; Orlandi G; Perini F; Tassi R; Tola MR; Sessa M; Toni D; Abbate R;
    Stroke; 2013 Oct; 44(10):2901-3. PubMed ID: 23908067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TT genotype of the MMP-9-1562C/T polymorphism may be a risk factor for thrombolytic therapy-induced hemorrhagic complications after acute ischemic stroke.
    Dusanovic Pjevic M; Jekic B; Beslac Bumbasirevic L; Vojvodic L; Damnjanovic T; Grk M; Maksimovic N; Pesic M; Gulic M; Trickovic J; Kacar K
    Pharmacotherapy; 2021 Jul; 41(7):562-571. PubMed ID: 33942334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma.
    Kunz P; Sähr H; Lehner B; Fischer C; Seebach E; Fellenberg J
    BMC Cancer; 2016 Mar; 16():223. PubMed ID: 26979530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic stroke.
    Lenglet S; Montecucco F; Mach F; Schaller K; Gasche Y; Copin JC
    Thromb Haemost; 2014 Aug; 112(2):363-78. PubMed ID: 24671655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes.
    Vukasovic I; Tesija-Kuna A; Topic E; Supanc V; Demarin V; Petrovcic M
    Clin Chem Lab Med; 2006; 44(4):428-34. PubMed ID: 16599837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIMP1, TIMP2, and TIMP4 are increased in aqueous humor from primary open angle glaucoma patients.
    Ashworth Briggs EL; Toh T; Eri R; Hewitt AW; Cook AL
    Mol Vis; 2015; 21():1162-72. PubMed ID: 26539028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.
    Nisar T; Hanumanthu R; Khandelwal P
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104360. PubMed ID: 31501036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover.
    Phillips PA; McCarroll JA; Park S; Wu MJ; Pirola R; Korsten M; Wilson JS; Apte MV
    Gut; 2003 Feb; 52(2):275-82. PubMed ID: 12524413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma MMP-9 and TIMP-1 levels on ICU admission are associated with 30-day survival.
    Jordakieva G; Budge-Wolfram RM; Budinsky AC; Nikfardjam M; Delle-Karth G; Girard A; Godnic-Cvar J; Crevenna R; Heinz G
    Wien Klin Wochenschr; 2021 Feb; 133(3-4):86-95. PubMed ID: 31932967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
    Seet RC; Rabinstein AA
    Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Investigation of Matrix Metalloproteinases, Tissue Inhibitors of Matrix Metalloproteinases, and Matrix Metalloproteinase/Tissue Inhibitors of Matrix Metalloproteinase Complexes and Their Networks in Apical Periodontitis.
    Martinho FC; Teixeira FF; Cardoso FG; Ferreira NS; Nascimento GG; Carvalho CA; Valera MC
    J Endod; 2016 Jul; 42(7):1082-8. PubMed ID: 27188765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Influence of Simvastatin on NGAL, Matrix Metalloproteinases and Their Tissue Inhibitors in Human Intraluminal Thrombus and Abdominal Aortic Aneurysm Tissue.
    Piechota-Polanczyk A; Demyanets S; Mittlboeck M; Hofmann M; Domenig CM; Neumayer C; Wojta J; Klinger M; Nanobachvili J; Huk I
    Eur J Vasc Endovasc Surg; 2015 May; 49(5):549-55. PubMed ID: 25800096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
    Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
    Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
    Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
    Pérez P; Kwon YJ; Alliende C; Leyton L; Aguilera S; Molina C; Labra C; Julio M; Leyton C; González MJ
    Arthritis Rheum; 2005 Sep; 52(9):2751-60. PubMed ID: 16142742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal profile of matrix metalloproteinases and their inhibitors in a human endothelial cell culture model of cerebral ischemia.
    Reuter B; Rodemer C; Grudzenski S; Couraud PO; Weksler B; Romero IA; Meairs S; Bugert P; Hennerici MG; Fatar M
    Cerebrovasc Dis; 2013; 35(6):514-20. PubMed ID: 23817219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory and metalloproteinases profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysis.
    Gori AM; Giusti B; Piccardi B; Nencini P; Palumbo V; Nesi M; Nucera A; Pracucci G; Tonelli P; Innocenti E; Sereni A; Sticchi E; Toni D; Bovi P; Guidotti M; Tola MR; Consoli D; Micieli G; Tassi R; Orlandi G; Sessa M; Perini F; Delodovici ML; Zedde ML; Massaro F; Abbate R; Inzitari D
    J Cereb Blood Flow Metab; 2017 Sep; 37(9):3253-3261. PubMed ID: 28266892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease.
    Senzaki H; Masutani S; Kobayashi J; Kobayashi T; Nakano H; Nagasaka H; Sasaki N; Asano H; Kyo S; Yokote Y
    Circulation; 2001 Aug; 104(8):860-3. PubMed ID: 11514369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.